Could MRI spot prostate cancer earlier in High-Risk men?

NCT ID NCT01990521

Ongoing Diagnosis Sponsor: Toronto Sunnybrook Regional Cancer Centre Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

Men with BRCA1 or BRCA2 gene mutations have a higher risk of early and aggressive prostate cancer. This study tests whether using a special MRI (multispectral 3T MRI) can find prostate cancer earlier than standard PSA and digital rectal exams. Sixty men aged 50 and older with BRCA mutations will get an MRI followed by a biopsy to see how well the MRI detects cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Multispectral 3T MRI and transrectal ultrasound-guided biopsy
What this could lead to: If successful, MRI could become a standard screening tool to catch prostate cancer earlier in men with BRCA mutations, potentially improving outcomes.
What could go wrong: This is a small, early study (60 participants) and it's unclear if MRI will be more effective than current PSA and DRE screening. The results may not apply to all men with BRCA mutations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Sunnybrook Odette Cancer Centre

Toronto, Ontario, M4N 3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.